Frontier Biotechnologies

Frontier Biotechnologies EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Frontier Biotechnologies (688221.SS) as of Nov 22, 2026 is -37.73. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -49.53 — a change of -23.83% (higher).

EV/OCF

-37.73

YoY

-23.83%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Frontier Biotechnologies is 2025 -37.73 . EV/OCF (Enterprise Value to Operating Cash Flow) of Frontier Biotechnologies was 2024 -49.53 . It decreases by -23.83% higher compared to the previous year.

The Frontier Biotechnologies EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-102.40 CNY
Jan 1, 2019
247.41 CNY
Jan 1, 2020
-49.82 CNY
Jan 1, 2021
-34.86 CNY
Jan 1, 2022
-29.69 CNY
Jan 1, 2023
-31.95 CNY
Jan 1, 2024
-49.53 CNY
Jan 1, 2025
-37.73 CNY
The Frontier Biotechnologies EV/OCF history
YEAREV/OCFYoY
-37.73-23.83%
-49.53+55.01%
-31.95+7.61%
-29.69-14.82%
-34.86-30.03%
-49.82-120.14%
247.41-341.61%
-102.40-73.58%
-387.63—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Frontier Biotechnologies Stock analysis

What does Frontier Biotechnologies do? Frontier Biotechnologies, Inc. develops and sells medicines through its product portfolio, including Aikening and the Combination regiment of Albuvirtide (ABT) + 3BNC117, which is in clinical stage for HIV treatment. The company also offers transdermal analgesic patch AB001 for muscle, skeleton, and joint pain, currently in clinical development. Frontier Biotechnologies operates within the China market and serves overseas markets with its pharmaceutical products. The company generates revenue primarily from the research, development, and sale of its clinical-stage medicines, targeting both domestic and international healthcare providers and distributors. Its products are positioned for treatment of HIV and pain management, with AB001 focusing on non-invasive pain relief solutions. Frontier Biotechnologies focuses on advancing its pipeline through clinical trials to bring these therapies to market. Frontier Biotechnologies, Inc. is a biotechnology firm headquartered in Nanjing, Jiangsu, with 495 full-time employees. It conducts its business activities in China and overseas, leveraging its R&D capabilities to develop innovative treatments for unmet medical needs. The firm's revenue streams are derived from the commercialization of its pipeline products once they reach the market. Frontier Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Frontier Biotechnologies stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Frontier Biotechnologies is -37.73 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Frontier Biotechnologies changed from -49.53 to -37.73, representing a -23.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Frontier Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Frontier Biotechnologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Frontier Biotechnologies

All Key Metrics — Frontier Biotechnologies